181 related articles for article (PubMed ID: 32374740)
1. A comprehensive analysis of metabolomics and transcriptomics in non-small cell lung cancer.
Ruiying C; Zeyun L; Yongliang Y; Zijia Z; Ji Z; Xin T; Xiaojian Z
PLoS One; 2020; 15(5):e0232272. PubMed ID: 32374740
[TBL] [Abstract][Full Text] [Related]
2. A Comprehensive Analysis of Metabolomics and Transcriptomics in Cervical Cancer.
Yang K; Xia B; Wang W; Cheng J; Yin M; Xie H; Li J; Ma L; Yang C; Li A; Fan X; Dhillon HS; Hou Y; Lou G; Li K
Sci Rep; 2017 Feb; 7():43353. PubMed ID: 28225065
[TBL] [Abstract][Full Text] [Related]
3. Metabolomic, transcriptomic and genetic integrative analysis reveals important roles of adenosine diphosphate in haemostasis and platelet activation in non-small-cell lung cancer.
Hoang LT; Domingo-Sabugo C; Starren ES; Willis-Owen SAG; Morris-Rosendahl DJ; Nicholson AG; Cookson WOCM; Moffatt MF
Mol Oncol; 2019 Nov; 13(11):2406-2421. PubMed ID: 31461552
[TBL] [Abstract][Full Text] [Related]
4. Cortisol, cortisone, and 4-methoxyphenylacetic acid as potential plasma biomarkers for early detection of non-small cell lung cancer.
Xiang C; Jin S; Zhang J; Chen M; Xia Y; Shu Y; Guo R
Int J Biol Markers; 2018 Aug; 33(3):314-320. PubMed ID: 29896992
[TBL] [Abstract][Full Text] [Related]
5. Metabolic network-based identification of plasma markers for non-small cell lung cancer.
Guo L; Li L; Xu Z; Meng F; Guo H; Liu P; Liu P; Tian Y; Xu F; Zhang Z; Zhang S; Huang Y
Anal Bioanal Chem; 2021 Dec; 413(30):7421-7430. PubMed ID: 34617154
[TBL] [Abstract][Full Text] [Related]
6. Combined metabolomics with transcriptomics reveals potential plasma biomarkers correlated with non-small-cell lung cancer proliferation through the Akt pathway.
Zheng J; Zheng Y; Li W; Zhi J; Huang X; Zhu W; Liu Z; Gong L
Clin Chim Acta; 2022 May; 530():66-73. PubMed ID: 35245482
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer.
Liu S; Chen X; Chen R; Wang J; Zhu G; Jiang J; Wang H; Duan S; Huang J
Oncotarget; 2017 May; 8(22):36354-36367. PubMed ID: 28422739
[TBL] [Abstract][Full Text] [Related]
8. Integration of metabolomics and machine learning revealed tryptophan metabolites are sensitive biomarkers of pemetrexed efficacy in non-small cell lung cancer.
Sun R; Fei F; Wang M; Jiang J; Yang G; Yang N; Jin D; Xu Z; Cao B; Li J
Cancer Med; 2023 Sep; 12(18):19245-19259. PubMed ID: 37605514
[TBL] [Abstract][Full Text] [Related]
9. Serum untargeted metabolomics reveal metabolic alteration of non-small cell lung cancer and refine disease detection.
Li J; Liu K; Ji Z; Wang Y; Yin T; Long T; Shen Y; Cheng L
Cancer Sci; 2023 Feb; 114(2):680-689. PubMed ID: 36310111
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics and lipidomics in non-small cell lung cancer.
Shi W; Cheng Y; Zhu H; Zhao L
Clin Chim Acta; 2024 Mar; 555():117823. PubMed ID: 38325713
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of microRNA-144-3p and its clinical value in non-small cell lung cancer: a comprehensive analysis based on microarray, miRNA-sequencing, and quantitative real-time PCR data.
Chen YJ; Guo YN; Shi K; Huang HM; Huang SP; Xu WQ; Li ZY; Wei KL; Gan TQ; Chen G
Respir Res; 2019 Mar; 20(1):48. PubMed ID: 30832674
[TBL] [Abstract][Full Text] [Related]
12. Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits.
Wu Z; Liu Z; Jiang X; Mi Z; Meng M; Wang H; Zhao J; Zheng B; Yuan Z
J Exp Clin Cancer Res; 2019 Aug; 38(1):341. PubMed ID: 31387622
[TBL] [Abstract][Full Text] [Related]
13. Identification of miR-210 and combination biomarkers as useful agents in early screening non-small cell lung cancer.
Hu X; Peng Q; Zhu J; Shen Y; Lin K; Shen Y; Zhu Y
Gene; 2020 Mar; 729():144225. PubMed ID: 31830514
[TBL] [Abstract][Full Text] [Related]
14. Predicting Diagnostic Gene Biomarkers for Non-Small-Cell Lung Cancer.
Liang B; Shao Y; Long F; Jiang SJ
Biomed Res Int; 2016; 2016():3952494. PubMed ID: 27579312
[TBL] [Abstract][Full Text] [Related]
15. Identification and Integrated Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer.
Liu X; Liu X; Li J; Ren F
Med Sci Monit; 2019 Dec; 25():9280-9289. PubMed ID: 31805030
[TBL] [Abstract][Full Text] [Related]
16. Blood-based gene expression signatures in non-small cell lung cancer.
Zander T; Hofmann A; Staratschek-Jox A; Classen S; Debey-Pascher S; Maisel D; Ansén S; Hahn M; Beyer M; Thomas RK; Gathof B; Mauch C; Delank KS; Engel-Riedel W; Wichmann HE; Stoelben E; Schultze JL; Wolf J
Clin Cancer Res; 2011 May; 17(10):3360-7. PubMed ID: 21558400
[TBL] [Abstract][Full Text] [Related]
17. Study of early stage non-small-cell lung cancer using Orbitrap-based global serum metabolomics.
Klupczynska A; Dereziński P; Garrett TJ; Rubio VY; Dyszkiewicz W; Kasprzyk M; Kokot ZJ
J Cancer Res Clin Oncol; 2017 Apr; 143(4):649-659. PubMed ID: 28168355
[TBL] [Abstract][Full Text] [Related]
18. The suppressive role of miR-542-5p in NSCLC: the evidence from clinical data and in vivo validation using a chick chorioallantoic membrane model.
He RQ; Li XJ; Liang L; Xie Y; Luo DZ; Ma J; Peng ZG; Hu XH; Chen G
BMC Cancer; 2017 Sep; 17(1):655. PubMed ID: 28927388
[TBL] [Abstract][Full Text] [Related]
19. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer.
Geng Q; Fan T; Zhang B; Wang W; Xu Y; Hu H
Respir Res; 2014 Nov; 15(1):149. PubMed ID: 25421010
[TBL] [Abstract][Full Text] [Related]
20. Differentially expressed and activated proteins associated with non small cell lung cancer tissues.
Nigro E; Imperlini E; Scudiero O; Monaco ML; Polito R; Mazzarella G; Orrù S; Bianco A; Daniele A
Respir Res; 2015 Jun; 16(1):74. PubMed ID: 26104294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
